4 quarters tracked · Beat rate 50% · Updated quarterly
| Period | Report Date | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $2.00 | $1.89 | -5.7% | Miss |
| Q4 2025 | 2025-12-31 | $2.73 | $2.51 | -8.0% | Miss |
| Q3 2025 | 2025-09-30 | $1.95 | $2.26 | +15.7% | Beat |
| Q2 2025 | 2025-06-30 | $1.75 | $2.61 | +49.1% | Beat |
Earnings Beat Rate
Bio-Rad Laboratories has beaten analyst EPS estimates in 2 of 4 tracked quarters (50% beat rate). Data sourced from SEC filings and analyst consensus. View full AI analysis →